<DOC>
	<DOCNO>NCT01890213</DOCNO>
	<brief_summary>This pilot study evaluate safety vaccine consist alphavirus replicon ( VRP ) encode protein ( CEA ) find associate cancer colon cancer patient stage III colon cancer . We also evaluate patient immune response vaccine .</brief_summary>
	<brief_title>Immunotherapy With CEA ( 6D ) VRP Vaccine ( AVX701 ) Patients With Stage III Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm stage III colorectal cancer determine AJCC 7th edition . Subjects must receive adjuvant postoperative chemotherapy meeting follow requirement : 1 . Chemotherapy must consist 5fluorouracilbased regimen without oxaliplatin least 6 cycle capecitabine without oxaliplatin 4 cycle . 2 . Chemotherapy must complete within 16 month start study treatment . Subjects rectal cancer must receive chemotherapy meeting follow requirement : 1 . Neoadjuvant chemotherapy , utilized , must consist 5fluorouracilbased regimen ( capecitabine ) radiation 2 . Adjuvant chemotherapy must consist 5fluorouracilbased regimen without oxaliplatin least 6 cycle capecitabine without oxaliplatin 4 cycle 3 . Chemotherapy must complete within 16 month start study treatment . Karnofsky performance status great equal 70 % Estimated life expectancy &gt; 6 month expect require systemic chemotherapy least 3 month . Age ≥ 18 year Adequate hematologic function : WBC ≥ 3000/microliter , Hgb ≥ 9 g/dL ( may transfuse use erythropoietin achieve level ) , platelets ≥ 100,000/microliter Adequate renal hepatic function , serum creatinine &lt; 1.5 mg/dL , bilirubin &lt; 1.5 mg/dL ( except Gilbert 's syndrome allow bilirubin ≤ 2.0 mg/dL ) , ALT AST ≤ 2.5 x upper limit normal . Ability understand provide sign informed consent fulfills Institutional Review Board 's guideline . Ability return Duke University Medical Center adequate followup , require protocol Patients active cytotoxic chemotherapy radiation therapy exclude . There exclusion base number prior chemotherapy , biologic , hormonal , experimental regimen . There must least 3 month prior CEAtargeted immunotherapy study treatment least 4 week prior therapy study treatment . Evidence metastatic disease . Patients history autoimmune disease , restrict , inflammatory bowel disease , systemic lupus erythematosus , ankylose spondylitis , scleroderma , multiple sclerosis . Patients serious intercurrent chronic acute illness , cardiac disease ( NYHA class III IV ) , hepatic disease , illness consider Principal Investigator unwarranted high risk investigational drug treatment . Patients medical psychological impediment probable compliance protocol exclude . Concurrent ( within last 5 year ) second malignancy non melanoma skin cancer , cervical carcinoma situ , control superficial bladder cancer . Presence active acute chronic infection include : urinary tract infection , HIV ( determine ELISA confirm Western Blot ) viral hepatitis ( determine HBsAg Hepatitis C serology ) . Patients HIV exclude base immunosuppression , may render unable respond vaccine ; patient chronic hepatitis exclude concern hepatitis could exacerbate injection . Patients steroid therapy ( immunosuppressive , azathioprine cyclosporin A ) exclude basis potential immune suppression . Patients must 6 week discontinuation steroid therapy ( except use premedication chemotherapy contrastenhanced study ) prior enrollment . Patients allergies component vaccine exclude protocol . Pregnant nursing woman exclude protocol since research may unknown harmful effect unborn child young child . If patient sexually active , patient must agree use medically acceptable form birth control receive treatment period 4 month follow last vaccination therapy . It know whether treatment use study could affect sperm could potentially harm child may father study . Patients acute chronic skin disorder interfere injection skin extremity subsequent assessment potential skin reaction exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>alphavirus</keyword>
	<keyword>colon cancer</keyword>
	<keyword>immune response</keyword>
	<keyword>CEA</keyword>
</DOC>